Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

John Fitzsimons

Vascular & Interventional Radiology Garland, TX Medical Doctor

NPI 1780613240 CMS profile 1239424

530 Clara Barton Blvd Ste 250, Garland, TX 75042

Open in the dashboard

General payments

$127,176

68 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Fitzsimons of Garland, TX is reported in the CMS Open Payments database as having received $127,176 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,158 4
2024 General $37,268 6
2023 General $37,886 10
2022 General $24,000 13
2021 General $3,480 24
2020 General $384 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Fitzsimons
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to John Fitzsimons were reported at $24,158. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year John Fitzsimons Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $384 $200 $68–$652 $114
2021 $3,480 $280 $99–$866 $132
2022 $24,000 $433 $137–$1,497 $149
2023 $37,886 $506 $152–$2,019 $160
2024 $37,268 $556 $175–$1,930 $164
2025 $24,158 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AngioDynamics, Inc. $125,072 32 payments
  2. Abbott Laboratories $751 6 payments
  3. Terumo Medical Corporation $410 4 payments
  4. Bard Peripheral Vascular, Inc. $258 2 payments
  5. Philips Electronics North America Corporation $204 3 payments
  6. Tactile Systems Technology Inc $139 10 payments
  7. Cardiva Medical, Inc. $139 4 payments
  8. Nevro Corp. $68 2 payments
  9. Boston Scientific Corporation $64 1 payment
  10. Medtronic, Inc. $37 2 payments
  11. Other $35 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Long term medical supply or device loan $122,305 16 payments
  2. Travel and Lodging $2,375 10 payments
  3. Food and Beverage $1,856 40 payments
  4. Education $640 2 payments
Products named General payments · program years 2020–2025
  1. Auryon Laser System 100-120 Vac Et $79,815 11 payments
  2. VenaCure 1470 Pro Et $20,653 8 payments
  3. Auryon Laser System 100-120 Vac Cv $16,958 2 payments
  4. VenaCure 1470 Pro Id $7,200 2 payments
  5. Omnilink Elite vascular stent system $386 2 payments
  6. NAVICROSS $336 2 payments
  7. SUPERA $327 2 payments
  8. AURYON LASER SYSTEM 100-120 VAC Pad $166 5 payments
  9. (6554) Peripheral Vascular Undivided $142 2 payments
  10. VenaCure 1470 Pro Vit $134 1 payment
  11. Other $1,021 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$24,840

Medicare's payments for the services billed

Medicare patients

329

Average age 74

Services billed

751

173 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 33%
Diabetes 29%
Cancer 28%
Chronic kidney disease 24%
Depression 23%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record